Rigel's (RIGL) R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
Tweet Send to a Friend
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that R788 produced significant clinical improvement in rheumatoid arthritis patients in the recently completed ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
